Market capitalization | $6.60m |
Enterprise Value | $5.92m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.29 |
P/S ratio (TTM) P/S ratio | 4.78 |
P/B ratio (TTM) P/B ratio | 3.36 |
Revenue growth (TTM) Revenue growth | -23.75% |
Revenue (TTM) Revenue | $1.38m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Predictive Oncology Inc:
1 Analyst has issued a forecast Predictive Oncology Inc:
Sep '24 |
+/-
%
|
||
Revenue | 1.38 1.38 |
24%
24%
|
|
Gross Profit | 0.07 0.07 |
80%
80%
|
|
EBITDA | -13 -13 |
9%
9%
|
EBIT (Operating Income) EBIT | -13 -13 |
11%
11%
|
Net Profit | -14 -14 |
24%
24%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Domestic, International, and Helomics. The Domestic and International segments focuses on STREAMWAY System product sales. The Helomics segment comprises of clinical testing and contract research. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.
Head office | United States |
CEO | Raymond Vennare |
Employees | 34 |
Founded | 2002 |
Website | predictive-oncology.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.